Research projects

Alligator’s early-stage research projects include several projects within immuno-oncology, based on Alligator’s bispecific format RUBY™, with components created using ALLIGATOR-GOLD® and FIND®. Alligator is actively seeking collaboration partners on this programs.

For further information, please contact Peter Ellmark, Chief Scientific Officer.

Peter Ellmark
    • Independent in relation to the Company and its management: No
    • Independent in relation to major shareholders: Yes
    • Holdings in Alligator: 98,720 shares, 250,000 warrants in program TO 2022/2025 I, and 600,000 warrants in program TO 2023/2026 I.
    • Other current positions: None
    Updated 2022-07-18